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Abstract 
Introduction : Community acquired pneumonia (CAP) is a major cause of hospital admissions 
and mortality in developed countries. Nevertheless, in about half of the cases a microbial 
etiology can`t be determined. The need to improve the diagnostic tools of this disease has led 
to the development of new techniques, such as Streptococcus pneumoniae urinary 
antigen. Objectives : To analyse the usefulness of the urinary antigen in determining the 
etiologic diagnosis of pneumonias and its influence in the antibiotherapy 
modification. Methods : Retrospective analysis of hospitalized patients in 2010 with CAP 
(n=226) and healthcare associated pneumonia (HCAP) [n=64] diagnosis whose urinary 
pneumococcal antigen has been analyzed. Results: Median age was significantly greater in 
HCAP. HCAP patients had more co-morbidities and higher severity scores. Twenty-one patients 
in the CAP group and 4 patients in the HCAP group had positive pneumococcal antigen. The 
sensibility of urinary antigen in determining pneumococcal pneumonias was 36% and the 
specificity 89%. Almost one quarter of the 25 patients with positive urinary antigen had 
appropriate reductions in antimicrobial spectra, which was not statistically significant when 
compared with the group with negative urinary antigen. There was a significant relation 
between a positive urinary antigen and pneumonia severity. Conclusions: Considering its high 
specificity, the urinary antigen is useful to confirm the presence of pneumococcal pneumonia. 
Potentially urinary antigen can help to avoid unnecessary treatments in hospitalized patients 
with CAP. 
 
Introduction 
Community acquired pneumonia (CAP) is a common disease and represents the main cause of 
hospital admissions and mortality by infectious diseases in developed countries1. The most 
frequent etiologic agent of CAP is Streptococcus pneumoniae (S. pneumoniae), responsible for 
30-40% of CAP whose etiology is determined. However, the etiology of CAP remains unknown 
in about 50% of the cases2. 
Recent studies suggest that S. pneumoniae may be underdiagnosed and it can, actually, 
represent a third of CAP of undetermined etiology2. 
The urge to improve the diagnosis of CAP is clearly justified by its high morbidity and mortality, 
excessive use of broad-spectrum antibiotics and the emergence of multiresistant strains1. 
According to the current recommendations of the Infectious Diseases Society of America 
(IDSA), it is good practice to investigate the etiologic agent responsible for the pneumonia, 
because it allows a significant change in the treatment, promotes the rational use of 
antibiotics, reduces costs, adverse effects and resistance2,3. 
In clinical practice, there are multiple obstacles to the diagnosis: 1) the sputum culture is 
limited by the difficulty of getting valid samples and adequate specimens; 2) frequent S. 
pneumoniae nasopharyngeal colonization in healthy individuals (causing uncertainty about the 
validity of the results); 3) identification of S. Pneumoniae in the blood or pleural fluid, which is 
the gold standard, has a low sensitivity (positive in only 15-30% of the cases); 4) beginning 
antibiotics before hospital admission (in about 30% if patients) decreases the sensitivity of the 
diagnostic tools4,5. 
Even though some invasive techniques (e.g., bronchoalveolar lavage) offer better samples, 
they aren’t routinely used, for they require specific training and may bring potential 
complications. 
With the objective of increasing the number of diagnosis, an immunochromatographic test 
was developed (BinaxNow® Streptococcus pneumoniae), that detects S. pneumoniae C 
polysaccharide (PnC) in urine samples. This test increases the number of etiological diagnosis, 
has proven to be fast, relatively sensitive and rather specific in the diagnosis of S. pneumoniae 
pneumonia in adults (the sensitivity is between 50-80% in patients without bacteraemia and 
75-85% in those with bacteraemia; the specificity is approximately 95%); the use of 
concentrated urine by selective ultrafiltration slightly increases the sensitivity of the test6. 
The airway colonization by S. pneumoniae or other streptococcal strains doesn’t seem to be 
related with false positives in adults, even in patients with chronic bronchitis (that is related 
with higher colonization rates)7. 
The excretion of antigens may last for several weeks (more than 3 months) after specific 
antibiotics6-11. 
The clinical usefulness of the pneumococcal urinary antigen (PUatg) is not totally established; 
therefore, the current recommendations don’t clearly define the situations in which the test 
should be obtained12-14. 
For example, according to the British Thoracic Society (BTS) and the IDSA, all the patients with 
moderate to severe CAP should do, at least, blood cultures, sputum cultures and urinary 
antigens for S. Pneumoniae15. 
In what concerns the use of PUatg in Healthcare Associated Pneumonias (HCAP), the evidence 
in literature is scarce, its usefulness in this context is controversial and the main societies don’t 
recommend it15-17. However, in clinical practice, the test is frequently requested, so we decided 
to include these patients to clarify the role of the PUatg in this population. 
 
Objectives 
This work evaluates the use of PUatg in a central hospital and has three main objectives: 1) to 
characterize the patients hospitalized with non-nosocomial pneumonia; 2) to evaluate the 
contribution of PUatg to the etiologic diagnosis of CAP and HCAP and 3) to analyze the 
antimicrobial therapy modifications according to microbiological results. 
Methods 
We conducted a retrospective study of the patients with the diagnosis of Pneumonia (code 
ICD9 480 till 488) from January to December 2010. 
We used the definition of Pneumonia by the World Health Organization (WHO)18. 
The patients with CAP and HCAP in whom the pneumococcal urinary antigens had been 
processed were enrolled in the study. The patients with Nosocomial Pneumonia (NP), 
Ventilator Associated Pneumonia (VAP), Aspiration Pneumonia/Pneumonitis (AspP) and 
patients without pneumococcal urinary antigen records were excluded. 
HCAP comprehends the pneumonias that were acquired before hospital admission or during 
the first 48h after admission, in patients that have at least one of the risk factors: 1) received 
antibiotics or chemotherapy in the previous 30 days; 2) with wounds that were treated in that 
period; 3) hospital stay for 2 or more days in the last 90 days; 4) dialysis in the last 30 days; 5) 
live in a institution; 6) have a close relative with a multi resistant organism. We therefore 
excluded nosocomial pneumonias that appear more than 8h after hospital admission or that 
are acquired in the hospital. 
For each patient, the comorbidities, scores of disease severity (Pneumonia Severity Index [PSI] 
and CURB-65), antibiotics, duration of the hospitalization, complications and 30 day mortality 
were recorded. 
In order to evaluate diagnostic accuracy of the test, we used two reference groups: 
1) definitive pneumococcal CAP – S. pneumoniae isolated in blood cultures (BC) or pleural fluid 
and 2) probable pneumococcal CAP – isolation of S. pneumoniae in the culture of bronchial 
secretions (BS). The BS that were considered valid consisted of sputum with less than 25 
squamous epithelial cells in the Gram stain examination. 
We recorded the therapeutic changes based on the results of the urinary antigens and 
classified the changes as: 1) optimal – narrowing of the antibiotic spectrum to Penicillin iv, 
Ampicillin iv or oral Amoxicillin; 2) appropriate – suspension of the macrolide, maintaining the 
beta-lactam antibiotic; 3) absent – without narrowing of the antibiotic spectrum or without 
treatment changes. 
The outcomes of the patients who received therapeutic changes according to the urinary 
antigens were also recorded. 
The data were inserted in Excel® and the statistical analysis was performed with the SPSS 19® 
software. We used chi-square or Fischer tests for proportions and means were compared using 
paramentric or non-parametric tests depending on the verified assumptions. A p value of 
≤0,05 was considered statistically significant. 
For the calculations of sensitivity, specificity, positive and negative predictive values, we 
considered true-positives the positive results of pneumococcal urinary antigen test in patients 
with definitive and probable pneumococcal pneumonia. We considered false-positives patients 
with positive PUatg and other agents in BC/BS. 
Results 
Of the 780 cases analysed after searching the ICD-9 codes in the database of the hospital, 290 
fulfilled the inclusion criteria. Of those, 77,9% (n=226) corresponded to CAP and 22,1% (n=64) 
to HCAP. The other 490 excluded pneumonias corresponded to NP (n=149), VAP (n=91), AspP 
(n=178) and patients without pneumococcal urinary antigen records (n=72). 
The demographic and clinical characteristics of the studied population are summarized in 
Table I. 
The mean hospital length of stay (and standard deviation) was 9,7 (7,4) days in CAP and 9,3 
(7,5) days in HCAP. There were not statistically significant differences in the mean hospital 
length of stay between CAP and HCAP (p=0,5). 
In the vast majority of patients (94,5%; n=274) BC were collected. A microorganism was 
isolated in 5,3% (n=12) of the patients with CAP and 9,4% (n=6) of the patients with HCAP. In a 
great amount of patients (62,4%; n=181), BS were collected. However, in 12,2% (n=22) of the 
samples the product was considered inappropriate by the microbiology laboratory (>25 
squamous epithelial cells). Those cases were excluded, leaving 120 samples in CAP and 39 in 
HCAP. An agent was isolated in 26,7% (n=32) of the patients with CAP and 25,6% (n=10) of the 
patients with HCAP. No agents were isolated in pleural effusions. Culture results are detailed in 
Table II. 
Streptococcus pneumoniae was isolated in 2 (0,9%) BC, and in the BS of 4,9% (n=11) patients 
with CAP and 1,6% (n=1) patient with HCAP. S. pneumoniae pneumonia was diagnosed 
exclusively by PUatg in 8,4% (n=19) patients with CAP and 4,7% (n=3) patients with HCAP. All S. 
pneumoniae isolates were penicillin-sensitive. 
In 3 of the patients with positive PUatg, other agents were isolated in the BC (Escherichia coli, 
Pseudomonas aeruginosa and Staphylococcus hominis). In another 2 positive cases, other 
agents (Haemophillus influenzae and Klebsiella pneumoniae) were isolated in BS. 
Crosstabulation between PUatg and BS/BC in presented in Table III. The results for sensitivity, 
specificity, positive and negative predictive values are presented in Table IV., and the relative 
frequencies of empirical therapy are described in Table V. 
Positive results from the PUatg test (n=25) led the clinicians to reduce the spectrum of 
antibiotic treatment in 6 (22,2%) patients. Noteworthy, the spectrum was reduced in 25 
(10,4%) patients with negative PUatg. In 19 (70,4%) patients with positive PUatg the treatment 
wasn`t modified. No statistically significant differences were found (p=0,054). 
In all cases (n=31) considered to have appropriate reductions, that was translated into a 
macrolide suspension. No optimal reductions were found. The median time to modification of 
empirical therapy was 3 days (IQR, 2 days) in patients with negative PUatg. In patients with 
positive PUatg, median time was 3,5 days (IQR, 2,25 days). 
In the group with positive PUatg (n=25), 5 patients (20,0%) were admitted to the ICU (p=0,05), 
4 (16,0%) had COPD (p=0,137), 20 (80,0%) had high mortality risk in PSI index score (p=0,994), 
and 17 (68,0%) in CURB-65 score (p=0,035), 6 (24,0%) had pneumonia related complications 
(p=0,777). 
No deaths were directly related to pneumonia. No positive PUatg were found in the previous 3 
months. 
 Table I. Baseline demographic and clinical characteristics of studied population. 
*non-parametric Mann-Whitney test 
**chi-square or Fisher exact test 
 
Table II. Etiologic profile 
Abbreviation: MRSA, methicilin resistant Staphylococcus aureus; BC, blood culture; BS, 
bronchial secretion. 
 
Table III. Relation between microbiological identification of Streptococcus pneumonia in 
bronchial secretions (BS) or blood and the result of the urinary antigen test, using Pearson’s 
Chi-square Test. 
 
Table IV. Calculation of sensitivity, specificity, positive and negative predictive values for 
urinary antigen test. 
Abbreviation: PP, pneumococcal pneumonia; Ss, sensitivity; Sp, specificity; PPV, positive 
predictive value; NPV, negative predictive value; CI95%, 95% confidence interval; PUatg +, 
positive S. pneumoniae urinary antigen. 
 
Table V. Relative frequencies of initial antibiotherapy. 
Discussion 
As we expected, the mean age was greater in HCAP than in CAP (p < 0,001). However, there 
wasn’t a significant difference in the length of stay in the hospital between HCAP and CAP 
(p=0,5). 
Patients with HCAP had more co-morbidities, such as active cancer (p=0,019), cerebrovascular 
disease (p<0,001) and chemotherapy (p=0,027). They had also higher severity scores - PSI-
PORT and CURB-65 (p <0,001 and p=0,004, respectively). 
In our setting, the conventional diagnostic tests had low rentability. The described data are 
inferior to those previously described in the literature2. These results may be due to low 
quality products collected in the emergency department and inclusion of non-septic patients. 
The PUatg is widely used and increases the number of etiologic diagnosis14,15,16. In our setting 
the sensitivity was 36% (CI95% 10-62), conferring the test low precision in diagnosis. Small 
sample size (few true-positives) implies great limitations in these calculations. The urine 
samples weren’t ultra-filtrated, possibly contributing to the low sensitivity found 17. Even 
though these numbers are inferior to the published data, sensitivity varies widely between 
series1,13,14. 
The specificity was high – 89% (IC95% 80-98), which is also consistent with the data previously 
described10,11. Based on these results, we can state that determining PUatg is useful to confirm 
the S. pneumoniae etiology. 
The number of false positives (FP) doesn’t seem to be increased in the patients with COPD 
(p=0,137), which is concordant to what was published in the literature before18. 
There were 3 cases considered FP. However, we can’t exclude the possibility of mixed 
infections or a previous exposure to S. pneumoniae (in the last 3 months)19. 
Until this date, few studies have confirmed the utility of PUatg in clinical practice. A study 
evaluated prospectively the use of PUatg in 168 patients admitted with CAP. Having a positive 
PUatg caused a change in antibiotics in 44 cases, without any significant change in the 
prognosis13. The only prospective randomized study that compared empirical treatment versus 
targeted treatment on the basis of the urine antigen results in hospitalised patients with 
CAP 20 did not show any benefits (economic- or prognostic-wise) in choosing antibiotics 
according to the results of PUatg. Moreover, the patients that received a microorganism-
directed antibiotic had more recurrences and complications. According to the authors, those 
recurrences and complications could be due to co-infection with agents not covered by those 
antibiotics. 
In our study, none of the patients with positive PUatg received antibiotics directed specifically 
to S. pneumoniae (optimal alteration). Six (24%) of the 25 patients with positive PUatg had a 
narrowing in the antibiotic spectrum considered appropriate (discontinuation of the 
macrolide). However, in spite of having a positive PUatg, the treatment wasn’t modified in 19 
(76%) of the patients. We have to point out that the macrolide was also suspended in 25 
(10,4%) of the patients with negative PUatg, with a borderline correlation between a positive 
PUatg result and the suspension of the macrolide (p=0,054). 
Surprisingly, the time interval until there was a change in the antibiotics was longer in the 
patients with positive PUatg (median - 3,5 days and IQR - 2,25 days). However, this time 
interval is difficult to determine in a retrospective study, because the reductions may be 
related to other microbiological results (blood or BS cultures). 
These data suggest that the physicians may not give much importance to the PUatg results. 
Perhaps doctors don’t trust the PUatg results enough to narrow the spectrum of antibiotics. 
This leads to a low clinical utility of PUatg. 
Our study suggests that the PUatg, because of its high specificity, can be useful to confirm the 
disease. However, the benefit can only be effective if the PUatg result determines a change in 
the therapeutic approach – such as a narrowing of the antibiotics spectrum – which was not 
the case in this series. 
In HCAP, the PUatg seems to be less important. This may be due to a lower preponderance of a 
S. pneumoniae etiology, a higher risk of false positives (by previous infections), and a selection 
of the agents caused by the frequent use of antibiotics. In this group, we didn`t find any utility 
in performing PUatg test. 
Our study has several limitations, most importantly it`s a retrospective study limiting the ability 
to calculate precisely antibiotherapy duration, antibiotherapy modification timing, 
microbiological results, clinical data and outcomes. In addition many patients (n=72) were 
excluded because PUatg test was not performed during hospitalization. 
Conclusions 
Considering its high specificity, the urinary antigen is useful to confirm the presence of S. 
pneumoniae pneumonia. Potentially urinary antigen can help to avoid unnecessary treatments 
in hospitalized patients with CAP. However, in HCAP the urinary antigen does not seem to be 
useful. 
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